lung cancer

You have access
The Holocaust Is a Significant and Independent Risk Factor of Late-Onset Cancers: A Systematic Review of the Literature and Original Data on Jewish Israeli, Jewish Non-Israeli and Non-Jewish Non-Israeli Survivors
EDOARDO VIRGILIO, DANIELE CAMILLI, GIORGIA GILI, FILIPPO MONTALI, CARLO SALVEMINI, ALFREDO ANNICCHIARICO, LORENZO PAGLIAI, ANDREA MORINI, ANDREA ROMBOLI and RENATO COSTI

Anticancer Research June 2021, 41 (6) 2745-2757; DOI: https://doi.org/10.21873/anticanres.15056
You have access
The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells
SEO YUN KIM, EUN-HUI JEONG, TAE-GUL LEE, HYE-RYOUN KIM and CHEOL HYEON KIM

Anticancer Research June 2021, 41 (6) 2885-2894; DOI: https://doi.org/10.21873/anticanres.15070
You have access
Estrogen Receptor β Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer
HIROKI SUGIURA, YASUHIRO MIKI, ERINA IWABUCHI, RYOKO SAITO, KATSUHIKO ONO, IKURO SATO, YOSHINORI OKADA and HIRONOBU SASANO

Anticancer Research May 2021, 41 (5) 2371-2381; DOI: https://doi.org/10.21873/anticanres.15012
You have access
Effective Control of Brain Metastases Irrespective of Distance from Isocenter in Single-isocenter Multitarget Stereotactic Radiosurgery
KEN AOKI, YUKIHIRO NAGATANI, KAZUO NOMA, TAKUYA TSUGAWA, NAOAKI KONO, YUKAKO KIDA, NAOKI HARADA, YOSHIHIDE TANOUE and YOSHIYUKI WATANABE

Anticancer Research May 2021, 41 (5) 2575-2581; DOI: https://doi.org/10.21873/anticanres.15036
You have access
Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D Versus 2D Culture Systems
HYUN-KYUNG LEE, MIN HYE NOH, SEUNG-WOO HONG, SEUNG-MI KIM, SUNG HYUN KIM, YEONG SEOK KIM, V. COURTNEY BROADDUS and DAE YOUNG HUR

Anticancer Research March 2021, 41 (3) 1261-1269; DOI: https://doi.org/10.21873/anticanres.14883
You have access
Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer
NORIAKI ITO, TAKESHI MASUDA, TAKU NAKASHIMA, SATOSHI NAKAO, KAKUHIRO YAMAGUCHI, SHINJIRO SAKAMOTO, YASUSHI HORIMASU, SHINTARO MIYAMOTO, HIROSHI IWAMOTO, KAZUNORI FUJITAKA, HIRONOBU HAMADA and NOBORU HATTORI

Anticancer Research March 2021, 41 (3) 1497-1506; DOI: https://doi.org/10.21873/anticanres.14908
You have access
Extracellular Water-to-total Body Water Ratio as an Objective Biomarker for Frailty in Lung Cancer Patients
TOMONORI HIRASHIMA, YOSHIMI NODA, HIDEKAZU SUZUKI, SHINGO NASU, AYAKO TANAKA, NAOKO MORISHITA, NORIKO RYOTA, KAORI IWATA, YUKARI OKADA and NORIO OKAMOTO

Anticancer Research March 2021, 41 (3) 1655-1662; DOI: https://doi.org/10.21873/anticanres.14928
You have access
Drug-induced Interstitial Lung Disease Has the Same Degree of Risk for Mortality as Old Age in Patients With Lung Cancer
KOHEI IWASHITA, TOMOHIRO MIZUNO, SATOMI KUMAZAWA, KAZUYOSHI IMAIZUMI and SHIGEKI YAMADA

Anticancer Research March 2021, 41 (3) 1707-1711; DOI: https://doi.org/10.21873/anticanres.14935
You have access
Reversion from Methionine Addiction to Methionine Independence Results in Loss of Tumorigenic Potential of Highly-malignant Lung-cancer Cells
JUN YAMAMOTO, YUSUKE AOKI, QINGHONG HAN, NORIHIKO SUGISAWA, YU SUN, KAZUYUKI HAMADA, HIROTO NISHINO, SACHIKO INUBUSHI, KENTARO MIYAKE, RYUSEI MATSUYAMA, MICHAEL BOUVET, ITARU ENDO and ROBERT M. HOFFMAN

Anticancer Research February 2021, 41 (2) 641-643; DOI: https://doi.org/10.21873/anticanres.14815
You have access
Newly Synthesized DNA Methyltransferase Inhibitors as Radiosensitizers for Human Lung Cancer and Glioblastoma Cells
CHAN WOO WEE, JIN HO KIM, HAK JAE KIM, HYUN-CHEOL KANG, SOO YOUN SUH, BEOM SOO SHIN, EUNSOOK MA and IL HAN KIM

Anticancer Research February 2021, 41 (2) 757-764; DOI: https://doi.org/10.21873/anticanres.14827

Main menu

User menu

Search

lung cancer

Pages